Kristie L. Kahl

In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.

The Food and Drug Administration approved Kanjinti, a biosimilar to the US-licensed Herceptin, marking it the fifth of its kind.

An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.

Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma.

The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

A practice improvement project at the Mayo Clinic helped to increase attention to family health history and identify those at risk for cancer.

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

In this week’s episode, we spoke with a patient and his doctor about genomic testing and how it can change treatment outcomes for patients with cancer.

The Food and Drug Administration granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

The Food and Drug Administration revealed its pilot program, designed to assist oncologists and patients requesting access to unapproved therapies in the cancer space.

After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.

The addition of Kisqali to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone.

The phase 3 POLO trial is the first randomized study to establish a biomarker-driven approach in the treatment of metastatic pancreatic cancer.

A mother-daughter duo participates in the Donna Foundation’s marathon weekend to fund breast cancer research and support patients.

The Food and Drug Administration granted a priority review to Darzalex in combination with Velcade (bortezomib), thalidomide and dexamethasone, also known as Vtd, for the front-line treatment of newly diagnosed patients with multiple myeloma.

In this episode of “CURE Talks Cancer,” we spoke with a patient, an advocate and a doctor to learn more about bladder cancer and what others should know about the disease.

In this episode, we spoke with a rare lymphoma survivor on how chimeric antigen receptor T-cell therapy saved her life.

Using Revlimid as a preventative treatment for smoldering multiple myeloma significantly reduced the risk for the precursor disease to progress into cancer, compared with just observation.

While many advances have been made in the treatment landscape of MCL, the need for curative treatment options may be where future research goes.

With no available diagnostic tests for the detection and/or monitoring of bladder cancer, researchers from the Medical College of Georgia at Augusta University may have two new urine tests that determine the disease’s severity and detect for its recurrence.

A small molecule drug may help to overcome resistance to Imbruvica in patients with MCL, according to preclinical study findings from The University of Texas MD Anderson Cancer Center.

In this week’s episode, we spoke with legendary broadcast journalist Katie Couric about serving as a cancer caregiver and her new initiative with Merck’s Your Cancer Game Plan, called “With Love, Me.”

A recent study showed that postmenopausal women demonstrated a significant reduction in the risk for bladder cancer after quitting smoking, highlighting the need for prevention and cessation programs in older women.

The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive AML.

The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of the agency approving pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor – a rare, benign lesion that can be locally aggressive and often recurring.